[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201390543A1 - Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат - Google Patents

Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат

Info

Publication number
EA201390543A1
EA201390543A1 EA201390543A EA201390543A EA201390543A1 EA 201390543 A1 EA201390543 A1 EA 201390543A1 EA 201390543 A EA201390543 A EA 201390543A EA 201390543 A EA201390543 A EA 201390543A EA 201390543 A1 EA201390543 A1 EA 201390543A1
Authority
EA
Eurasian Patent Office
Prior art keywords
biomarkers
concentration
acetate
glatiramer acetate
gletiramer
Prior art date
Application number
EA201390543A
Other languages
English (en)
Other versions
EA025780B1 (ru
Inventor
Ллойд Х. Каспер
Жаклин И. Смит
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201390543A1 publication Critical patent/EA201390543A1/ru
Publication of EA025780B1 publication Critical patent/EA025780B1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Способ лечения объекта-человека, страдающего рассеянным склерозом или перенесшего однократный клинический приступ, соответствующий рассеянному склерозу, с помощью фармацевтической композиции, включающей глатирамер ацетат и фармацевтически приемлемый носитель, причем способ включает стадии определения того, отвечает ли объект-человек на глатирамер ацетат, путем оценки биомаркера, выбранного из группы, состоящей из концентрации IL-17, концентрации TNF-α, концентрации IL-2 и концентрации IFN-γ или их комбинации в крови объекта-человека, и стадии введения объекту-человеку фармацевтической композиции, включающей глатирамер ацетат и фармацевтически приемлемый носитель, только если объект-человек идентифицирован как отвечающий на глатирамер ацетат.
EA201390543A 2010-10-11 2011-10-10 Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат EA025780B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39196810P 2010-10-11 2010-10-11
PCT/US2011/055588 WO2012051106A1 (en) 2010-10-11 2011-10-10 Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate

Publications (2)

Publication Number Publication Date
EA201390543A1 true EA201390543A1 (ru) 2013-09-30
EA025780B1 EA025780B1 (ru) 2017-01-30

Family

ID=45938670

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390543A EA025780B1 (ru) 2010-10-11 2011-10-10 Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат

Country Status (15)

Country Link
US (3) US8709433B2 (ru)
EP (1) EP2627669B1 (ru)
JP (2) JP2013541010A (ru)
KR (1) KR20140019296A (ru)
AU (1) AU2011313842B2 (ru)
BR (1) BR112013008573A2 (ru)
CA (1) CA2814500A1 (ru)
EA (1) EA025780B1 (ru)
ES (1) ES2602977T3 (ru)
IL (1) IL225118A (ru)
MX (1) MX347871B (ru)
NZ (2) NZ703122A (ru)
PL (1) PL2627669T3 (ru)
PT (1) PT2627669T (ru)
WO (1) WO2012051106A1 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2949335B1 (en) 2009-08-20 2017-01-04 Yeda Research & Development Company, Ltd. Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
MX347871B (es) 2010-10-11 2017-05-16 Teva Pharmaceutical Ind Ltd * Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CA2884267A1 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
CN105377308B (zh) 2013-03-14 2019-07-26 迈兰公司 醋酸格拉替雷响应生物标志物mRNA效力测定
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
JP2016533728A (ja) 2013-10-24 2016-11-04 マイラン・インコーポレイテッドＭｙｌａｎ Ｉｎｃ． 酢酸グラチラマー製品の免疫学的同一性を評価するためのヒトｔ細胞株アッセイ
US20160213633A1 (en) * 2015-01-28 2016-07-28 Teva Pharmaceutical Industries, Ltd. Method of inducing anti-glatiramer acetate antibody response
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2018242998B2 (en) 2017-03-26 2023-11-02 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
KR102734078B1 (ko) * 2018-08-30 2024-11-25 싸토리우스 바이오애널리티컬 인스트루먼츠, 아이엔씨 단일 샘플 중 저농도 및 고농도 단백질의 농도 결정 방법

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
CA2794705C (en) 1998-09-25 2017-07-18 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU6281599A (en) 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
EP1128839A4 (en) 1998-11-12 2002-10-09 Yeda Res & Dev PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD
HK1054507B (zh) 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相關肽和多肽及其處理過的t細胞在神經保護性治療中的用途
CA2400374A1 (en) 2000-02-18 2001-08-23 Adrian Gilbert Oral, nasal and pulmonary dosage formualtions of copolymer 1
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
PL363431A1 (en) 2000-06-05 2004-11-15 Teva Pharmaceuticals Industries, Ltd. The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
CN100438906C (zh) 2000-06-07 2008-12-03 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
ATE475883T1 (de) 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
RU2303996C2 (ru) 2001-12-06 2007-08-10 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Вакцина и способ лечения болезней двигательных нейронов
WO2004043995A2 (en) 2002-11-13 2004-05-27 Apotex Pharmachem Inc. Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
CA2512735C (en) 2003-01-07 2016-03-08 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
RU2339397C2 (ru) 2003-01-21 2008-11-27 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Сор1 для лечения воспалительных заболеваний кишечника
CA2518079A1 (en) 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis
CA2525771A1 (en) 2003-05-14 2004-12-02 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2005007673A2 (en) * 2003-07-03 2005-01-27 Rush University Medical Center Immunogenic peptides
CN1886506B (zh) 2003-09-29 2012-05-30 中外制药株式会社 在nk细胞中表达的蛋白质
EP1680087A1 (en) 2003-10-31 2006-07-19 Teva Pharmaceutical Industries Limited Nanoparticles for drug delivery
AU2004288654B2 (en) 2003-11-12 2009-12-03 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
CA2558380A1 (en) 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
CA2579038A1 (en) * 2004-09-02 2006-03-16 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
EP1797109B1 (en) 2004-09-09 2016-02-24 Yeda Research And Development Co., Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
RS52265B (en) 2004-09-09 2012-10-31 Teva Pharmaceutical Industries Ltd. PROCESS FOR OBTAINING TRIFLUORACETYL ACETATE GLATIRAMER MIXTURES USING PURE HYDROCHLORIC ACID
WO2006050122A1 (en) 2004-10-29 2006-05-11 Sandoz Ag Processes for preparing glatiramer
UA93669C2 (ru) 2005-02-02 2011-03-10 Тева Фармасьютикл Индастриз, Лтд. Способ приготовления полипептидной смеси c использованием гидрогенолиза
RS52867B (en) 2005-02-17 2013-12-31 Teva Pharmaceutical Industries Ltd. GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
US20100167983A1 (en) 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
EP1891233A4 (en) 2005-04-25 2010-03-24 Yeda Res & Dev MARKERS ASSOCIATED WITH THERAPY EFFECTIVENESS OF GLATIRAMERATE ACETATE
WO2007030573A2 (en) 2005-09-09 2007-03-15 Yeda Research And Development Co. Ltd. Polypeptides useful for molecular weight determinations
DK1929297T3 (da) * 2005-09-29 2013-03-04 Caprion Proteomics Usa Llc Biomarkører for dissemineret sklerose og fremgangsmåder til anvendelse heraf
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
WO2007146331A1 (en) 2006-06-12 2007-12-21 Teva Pharmaceutical Industries, Ltd. Tannate salt form of polypeptide mixtures, their preparation and use
JP2009542864A (ja) 2006-07-05 2009-12-03 モメンタ ファーマシューティカルズ インコーポレイテッド コポリマー１の調製のための改良法
WO2009002515A1 (en) * 2007-06-25 2008-12-31 Vertex Pharmaceuticals Incorporated Th-17 cells
BRPI0819001A2 (pt) 2007-11-28 2014-10-07 Teva Pharma "método para retardar o acesso de esclerose múltipla clinicamente defenitiva em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão da atividade de doença monitorada por imagem latente de ressonância magnética (mri) em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão dos sintomas de esclerose múltipla definitiva em um paciente, método para reduzir a freqüência de recidiva em um paciente que experimentou um ataque clínico simples sugestivo de esclerose múltipla e que tem pelo menos uma lesão sugestiva de esclerose múltipla, método para retardar a progressão para a esclerose múltipla clinicamente definitiva em um paciente que apresenta um primeiro evento clínico sugestivo de esclerose múltipla e pelo menos uma lesão sugestiva de esclerose múltipla, uso de acetato de glatiramer e acetato de glatiramer
EP2113560A1 (en) * 2008-04-28 2009-11-04 TXCell Compositions for treating an arthritic condition
US20100167421A1 (en) * 2008-09-19 2010-07-01 University Of Utah Research Foundation Methods for identification and prediction of multiple sclerosis disease and therapy response
PT2275086E (pt) 2009-07-15 2012-05-18 Teva Pharma Formulação de volume reduzido de acetato de glatirâmero e métodos de administração
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
EP2949335B1 (en) * 2009-08-20 2017-01-04 Yeda Research & Development Company, Ltd. Low frequency glatiramer acetate therapy
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MX347871B (es) 2010-10-11 2017-05-16 Teva Pharmaceutical Ind Ltd * Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero.
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CA2884267A1 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
HK1214133A1 (zh) 2012-12-21 2016-07-22 Teva Pharmaceutical Industries Ltd. 醋酸格拉默的口腔透黏膜給藥
JP2016503803A (ja) 2012-12-21 2016-02-08 テバ ファーマシューティカル インダストリーズ リミティド 酢酸グラチラマーの経粘膜送達
JP2016504039A (ja) 2013-01-04 2016-02-12 テバ ファーマシューティカル インダストリーズ リミティド グラチラマーアセテート関連医薬品の特性決定
EP2968559A4 (en) 2013-03-12 2016-11-02 Teva Pharma RITUXIMAB INDUCTION THERAPY FOLLOWED BY GLATIRAMERACETATE THERAPY
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product

Also Published As

Publication number Publication date
AU2011313842A1 (en) 2013-05-30
US9063153B2 (en) 2015-06-23
JP2016188214A (ja) 2016-11-04
US20120121619A1 (en) 2012-05-17
ES2602977T3 (es) 2017-02-23
JP2013541010A (ja) 2013-11-07
WO2012051106A1 (en) 2012-04-19
MX2013003929A (es) 2013-07-05
PL2627669T3 (pl) 2017-02-28
EP2627669A1 (en) 2013-08-21
EP2627669B1 (en) 2016-08-17
US9625473B2 (en) 2017-04-18
US20150241446A1 (en) 2015-08-27
EA025780B1 (ru) 2017-01-30
IL225118A (en) 2017-10-31
AU2011313842B2 (en) 2016-12-15
CA2814500A1 (en) 2012-04-19
KR20140019296A (ko) 2014-02-14
NZ703122A (en) 2016-06-24
BR112013008573A2 (pt) 2016-07-12
US8709433B2 (en) 2014-04-29
MX347871B (es) 2017-05-16
EP2627669A4 (en) 2014-04-09
NZ609938A (en) 2015-11-27
US20140294899A1 (en) 2014-10-02
PT2627669T (pt) 2016-11-24

Similar Documents

Publication Publication Date Title
EA201390543A1 (ru) Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
Sun et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia
Ferrucci et al. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
HK1213830A1 (zh) 用於預測醋酸格拉替雷臨床反應的生物標誌物
EA201500219A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
BR112012030625A2 (pt) uso de inibidores de tirosina quinase de bruton (btk)
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
UA116871C2 (uk) СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII
IN2012DN06309A (ru)
WO2011133668A3 (en) Methods and compositions for the treatment of cancer
MY178654A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2014005996A (es) Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia.
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
HK1209758A1 (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
WO2010031749A9 (en) Compositions and methods for detecting tlr3
WO2014140362A3 (en) Lymphocyte biomarkers for determining the clinical response to therapy with mesenschymal stromal cells(msc)
HRP20180130T1 (hr) Protutumorsko sredstvo i postupak predviđanja terapijskog učinka za pacijente s kolorektalnim rakom s mutacijom kras
Schmid et al. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function
RU2016147122A (ru) Применение серелаксина для снижения gdf-15
WO2010116003A3 (en) Method for predicting the response of non-small cell lung cancer patients to targeted pharmacotherapy
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
Auld et al. Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium
WO2017167942A8 (en) Method for predicting the response of melanoma patients to a medicament
TN2012000607A1 (en) Method for predicting a therapy response in subjects with multiple sclerosis

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU